AZ12601011 is an orally bioavailable, specific TGFBR1 kinase inhibitor with an IC50 of 18 nM and a Kd of 2.9 nM. AZ12601011 inhibits phosphorylation of SMAD2 via specificly inhibiting ALK4, TGFBR1, and ALK7. AZ12601011 inhibits mammary tumor growth . References: [1]. Spender LC, et al. Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor βSuperfamily Type 1 Receptors. Mol Pharmacol. 2019 Feb;95(2):222-234.

纯度：≥98%